Sarah M. Bernhard

Sarah M. Bernhard

Auto-generated profile, based on publicly available information

Sarah M. Bernhard

Center for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Neuron
Verified
Journal Article
Closed access
NANicholas J. Audette
Nicholas J. Audette
SBSarah M. Bernhard
Sarah M. Bernhard
ARAjit Ray
Ajit Ray
LSLuke T. Stewart
Luke T. Stewart
ABAlison Barth
Alison Barth

11 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ADAmal El Daibani
Amal El Daibani
JPJoseph M. Paggi
Joseph M. Paggi
KKKuglae Kim
Kuglae Kim
YLYianni D. Laloudakis
Yianni D. Laloudakis
PPPetr Popov
Petr Popov
TCTao Che/Washington Che
Tao Che/Washington Che
The κ-opioid receptor (KOR) has emerged as an attractive drug target for pain management without addiction, and biased signaling through particular pathways of KOR may be key to maintaining this benefit while minimizing side-effect liabilities. As for most G protein-coupled receptors (GPCRs), however, the molecular mechanisms of ligand-specific signaling at KOR have remained unclear. To better understand the molecular determinants of KOR signaling bias, we apply structure determination, atomic-level molecular dynamics (MD) simulations, and functional assays. We determine a crystal structure of KOR bound to the G protein-biased agonist nalfurafine, the first approved KOR-targeting drug. We also identify an arrestin-biased KOR agonist, WMS-X600. Using MD simulations of KOR bound to nalfurafine, WMS-X600, and a balanced agonist U50,488, we identify three active-state receptor conformations, including one that appears to favor arrestin signaling over G protein signaling and another that appears to favor G protein signaling over arrestin signaling. These results, combined with mutagenesis validation, provide a molecular explanation of how agonists achieve biased signaling at KOR.

8 February 2021 in eLife
Verified
Journal Article
Open access
RURajendra Uprety
Rajendra Uprety
TCTao Che
Tao Che
SZSaheem A Zaidi
Saheem A Zaidi
SGSteven G Grinnell
Steven G Grinnell
BVBalázs R Varga
Balázs R Varga
SMSusruta Majumdar
Susruta Majumdar
Controlling receptor functional selectivity profiles for opioid receptors is a promising approach for discovering safer analgesics; however, the structural determinants conferring functional selectivity are not well understood. Here, we used crystal structures of opioid receptors, including the recently solved active state kappa opioid complex with MP1104, to rationally design novel mixed mu (MOR) and kappa (KOR) opioid receptor agonists with reduced arrestin signaling. Analysis of structure-activity relationships for new MP1104 analogs points to a region between transmembrane 5 (TM5) and extracellular loop (ECL2) as key for modulation of arrestin recruitment to both MOR and KOR. The lead compounds, MP1207 and MP1208, displayed MOR/KOR Gi-partial agonism with diminished arrestin signaling, showed efficient analgesia with attenuated liabilities, including respiratory depression and conditioned place preference and aversion in mice. The findings validate a novel structure-inspired paradigm for achieving beneficial in vivo profiles for analgesia through different mechanisms that include bias, partial agonism, and dual MOR/KOR agonism.

13 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
BVBalazs R. Varga
Balazs R. Varga
SBSarah M. Bernhard
Sarah M. Bernhard
ADAmal El Daibani
Amal El Daibani
SZSaheem A. Zaidi
Saheem A. Zaidi
JLJordy H. Lam
Jordy H. Lam
TCTao Che/Washington Che
Tao Che/Washington Che
Chronic pain and opioid overdose deaths highlight the need for non-addictive analgesics with novel mechanisms. The δ opioid receptor (δOR) is a promising target, as it lacks the respiratory depression associated with µ opioid receptor (µOR) agonists. However, early δOR full agonists caused seizures, limiting their clinical use. Partial δOR agonists may offer more controlled receptor activation than full agonists, but their development has been hindered by uncertainty regarding the molecular mechanism of partial agonism. Here we show that C6-Quino, a bitopic ligand developed through structure-based design, acts as a selective δOR partial agonist. Functional studies reveal that C6-Quino shows differential activity at G-protein and arrestin pathways and interacts with the sodium binding pocket, confirmed through cryo-EM analysis. C6-Quino demonstrates oral activity, analgesic activity in chronic pain models without causing δOR-related seizures and µOR-related adverse effects which have limited opioid usage in recent times. This discovery outlines a new strategy for developing δOR-targeted analgesics and provides a framework for optimizing signaling profiles of other Class A GPCRs.

8 January 2024 in The FEBS Journal
Verified
Journal Article
Closed access
SBSarah M. Bernhard
Sarah M. Bernhard
JHJianming Han
Jianming Han
TCTao Che/Washington Che
Tao Che/Washington Che

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
ARAjit Ray
Ajit Ray
SBSarah M. Bernhard
Sarah M. Bernhard
DKDika A. Kuljis
Dika A. Kuljis
Marcel BruchezMarcel Bruchez
Marcel Bruchez
ABAlison Barth
Alison Barth
Background: Alzheimer’s disease (AD) has long been described as a disease arising from progressive loss of synapses and cell death. While this is certainly true for the late stages of AD when patient present with clinical symptoms, it has increasingly become a focus of research that early AD may be paradoxically characterized by hyperexcitability and hyperactivity of neurons, specifically in hippocampal CA1 pyramidal neurons. In this study using a transgenic animal model of AD, we investigated whether an alteration in input‐specific synapse numbers could explain this early hyperactivity.Method: B6C3‐Tg(APPswe,PSEN1dE9) mice (APP/PS1) and wild‐type littermates of different ages and both sexes were injected with our novel pan‐synaptic labeling reagent (AAV1‐FAPpost) (Kuljis et al, 2019) in the dorsal hippocampal CA1 region. Labeled pyramidal cells were reconstructed and quantitative synaptic analysis across dendritic compartments was performed.Result: Even at postnatal day 21, CA1 pyramidal neurons from mutant mice showed an increase in the number of medial apical synapses (site for CA3 inputs) and a decrease in distal apical tuft synapses (site for entorhinal inputs), that may persist through adulthood. Proximal apical and basal synapses remained unaffected. Similar analysis in aged transgenic animals (13‐14 months) showed a uniform loss of synapses across all compartments.Conclusion: The compartment‐specific increase in CA3 to CA1 synapses during early development suggests that APP/amyloid‐β may be associated with abnormal synapse formation or stabilization. This increase in excitatory connectivity is consistent with hippocampal hyperexcitability that has been described in preclinical AD. This aberrant increase in CA3 may arise to compensate for the loss of entorhinal inputs and delay the onset of behavioral deficits. Our study demonstrates how AD pathology may progressively damage neural circuit function by inducing primary synaptic deficits and aberrant compensatory reweighting of other synaptic connections.